法人別リリース

Baylor College of Medicine and Miraca Holdings Agree to Joint Venture on Clinical Genetic Testing

みらかHD — Fri, 31 Oct 2014 23:02:52 +0900

2014年10月31日
みらかホールディングス株式会社
Baylor College of Medicine and Miraca Holdings Agree to Joint Venture on Clinical Genetic Testing
Baylor College of Medicine and Miraca Holdings
Agree to Joint Venture on Clinical Genetic Testing

HOUSTON ー (Oct. 31, 2014) -- Baylor College of Medicine and Miraca Holdings Inc., today  agreed on a joint venture in which the College will share ownership and governance of its clinical genetics diagnostic laboratories with the Japan-based international healthcare company that has a focus on clinical diagnostics and laboratory tests.

Baylor Miraca Genetics Laboratories will be built on Baylor’s existing Medical Genetics Laboratories which engages in clinical laboratory genetic testing. The transaction is subject to regulatory approvals and other customary closing conditions.

The jointly-owned clinical diagnostic venture will be headquartered in Houston.  The parties expect, initially, that the joint venture will be staffed by approximately 225 people.

Baylor has provided diagnostics services for over 35 years and is the No. 1 National Institutes of Health-funded genetics program.  It also is home to one of three U.S.-based large-scale genome sequencing centers funded by the NIH. Baylor will continue to independently drive its genetic diagnostic research agenda and the Joint Venture is expected to fully support the academic mission of the College’s Department of Molecular and Human Genetics.

All Baylor faculty involved in clinical diagnostics will remain Baylor faculty members and employees.  The College’s educational training programs in genetics and genome sequencing will continue operating through a formal academic affiliation with the Joint Venture, enabling trainees to have an opportunity to expand their laboratory diagnostic skills in a larger enterprise with samples coming from around the world.

Miraca, a holding company operating in the healthcare sector, is dedicated to in-vitro diagnostic, clinical laboratory testing and other healthcare-related businesses through its subsidiaries such as Fujirebio Inc., one of the major domestic in vitro diagnostic reagent manufacturers, and SRL, Inc., the largest clinical laboratory testing company in Japan. Miraca also has the largest U.S. independent anatomic pathology business, Miraca Life Sciences, headquartered in Irving, Texas, and is continuing to expand its footprint outside Japan. Miraca will provide its experience and capability to commercialize the Joint Venture.

Dr. Paul Klotman, president, CEO and executive dean of BCM, said, “This partnership will bring together our top-ranked genetics program with a leading diagnostics company. The result will be an opportunity for tremendous growth of our clinical genetics testing program, while ensuring the quality of diagnostics to patients and healthcare providers on an international level.”

“Academic medical centers and teaching hospitals in Houston have lagged behind other areas of the country in commercializing medical inventions developed in their laboratories,” said Klotman. “With partnerships such as this, the potential for growing biotech into a major economic driver for Houston and the Texas Medical Center is tremendous.”

Klotman added, “What makes this venture so beneficial to our patients and community is that it pairs the academic leadership and innovation of a highly ranked Baylor program with the business acumen of a well-run, well-recognized strategic partner.”

Dr. Hiromasa Suzuki, president and CEO of Miraca, said, “We will aim to collaborate closely with Baylor, a pioneer in genetic testing, with respect to research, development and commercialization in order to continuously supply innovative genetic testing services to our customers.”

“We believe this important Joint Venture will lead Miraca to become a top-tier provider with a strong operating base of innovative genetic business in the U.S.,” he said.

About Miraca Holdings：
Miraca Holdings, a Japan-based holding company with group net sales of JPY203.4 billion (FYE 3/2014), is engaged in the following three business segments in the healthcare sector : (1) development, manufacture, and commercialization of in vitro diagnostics, (2) clinical laboratory testing, and (3) other healthcare related businesses, which are conducted by its subsidiaries and affiliates including Fujirebio Inc., a leading supplier of in vitro diagnostics in Japan, and SRL, Inc. (“SRL”), Japan’s largest commercial laboratory. SRL offers comprehensive clinical laboratory testing services to medical institutes throughout the nation, ranging from general testing to esoteric testing including gene-based tests.

About Baylor College of Medicine：
Baylor is a top tier medical school for research with $363 million in research support, more than 90 research and patient care centers and units and over 3,000 students, residents and fellows. Medical Genetic Laboratories at Baylor offers a broad range of testing from traditional cytogenetics to chromosomal microarray analysis and next generation sequencing. MGL is located in Houston’s Texas Medical Center with over 200 employees, over 3,000 tests available and clients in all 50 states and in 16 countries. MGL’s lab is well-equipped with cutting edge diagnostic equipment, allowing it to efficiently generate the most accurate clinical genetic data.

＜Media Inquiries＞
Baylor College of Medicine
Lori Williams
loriw@bcm.edu
TEL: 713-798-4710, 713-775-6912 (cell)

Miraca Holdings Inc.
Hiroaki Kimura
Executive Officer
hk-kimura@miraca-holdings.co.jp

Miraca Life Sciences社によるPLUS Diagnostics社買収のお知らせ

みらかHD — Tue, 22 Oct 2013 18:00:14 +0900

2013年10月22日
みらかホールディングス株式会社
Miraca Life Sciences社によるPLUS Diagnostics社買収のお知らせ
米国で病理検査サービスを専門に提供している当社子会社のMiraca Life Sciences社（以下、「MLS」）は、米国で同種サービスを提供しているPLUS Diagnostics社（以下、「PLUS」）を、投資会社であるWater Street Healthcare Partnersから買収（以下、「本件買収」）いたしましたのでお知らせします。

本件買収において、MLSはPLUSを、借入金返済額を含む総額83.1百万米ドルで買収いたしました。PLUSの売上高は、2012年が75.4百万米ドル、2013年上期が34.2百万米ドルです。
本件買収により、MLSは全米最大規模の独立系病理検査サービス会社になるとともに、両者が持つリソースの有効活用とコストシナジー効果により、より強固で安定したビジネス基盤を構築することができると考えております。

　本件による当社連結業績への影響については現在精査中であり、本件買収の概要とともに11月に開催予定の2014年3月期第2四半期決算説明会にてお知らせいたします。

PLUS Diagnosticsについて
　PLUS Diagnostics（本店：米国カリフォルニア州）は、泌尿器、消化器、血液等の専門分野をカバーする、米国有数の病理検査企業です。ニュージャージー州とカリフォルニア州にラボをもち、約300名の従業員を擁しております。

Miraca Life Sciencesについて
　Miraca Life Sciences（本店：米国テキサス州）は、全米の顧客（医師及び専門診療所等）向けに高品質な病理検査サービスを4つの専門分野（消化器、皮膚、血液、泌尿器）において提供し、多くの顧客より高い信頼を得ている病理検査企業です。
MLSは、2011年11月の買収により、みらかホールディングスの100%子会社となりました。

以上

弊社創始者　藤田　光一郎　逝去のお知らせ

みらかHD — Thu, 31 Jan 2013 15:01:41 +0900

2013年1月31日
みらかホールディングス株式会社
弊社創始者　藤田　光一郎　逝去のお知らせ
弊社創始者　藤田　光一郎　逝去のお知らせ

弊社の創始者であり、元富士レビオ株式会社会長および、元株式会社エスアールエル会長の藤田　光一郎（ふじた　こういちろう、85歳）儀においては、去る1月24日、骨髄異形成症候群のため、永眠いたしました。
ここに生前のご厚誼を深謝し、謹んでお知らせ申し上げます。

通夜・告別式は、近親者にて、既に執り行わせていただきました。
後日、お別れの会を開催いたしますが、詳細は確定次第、あらためてご案内申し上げます。

なお誠に勝手ながら、ご香典、ご供花、ご供物、ご弔電は固くご辞退させていただきます。

故人の略歴
昭和3年1月11日生まれ、東京都出身
昭和24年3月　　現　金沢大学医学部卒業
昭和29年秋　　　東京医科歯科大学で博士号取得
昭和39年8月　　富士臓器製薬株式会社（現　富士レビオ株式会社）代表取締役社長
昭和45年6月　　株式会社スペシアルレファレンスラボラトリー（現　株式会社エスアールエル）代表取締役社長
昭和63年3月　　富士レビオ株式会社　代表取締役会長
平成7年7月　　　株式会社エスアールエル　代表取締役会長

趣味
クラシック音楽鑑賞、旅行、山歩き

本件に関するお問い合わせ
みらかホールディングス株式会社　
総務人事部　総務グループ
電話番号：03-5909-3335

以　上

法人別リリース

Baylor College of Medicine and Miraca Holdings Agree to Joint Venture on Clinical Genetic Testing

Miraca Life Sciences社によるPLUS Diagnostics社買収のお知らせ

弊社創始者 藤田 光一郎 逝去のお知らせ

弊社創始者　藤田　光一郎　逝去のお知らせ